SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 03/27/2026 at 13:00, 2 months 22 days ago

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
Sanofi's Sarclisa subcutaneous formulation via on-body injector recommended for EU approval by CHMP for multiple myeloma treatment, offering innovative delivery. Final decision expected soon

Multiple Myeloma Sarclisa CHMP Recommendation On-Body Injector Subcutaneous Formulation
BRIEF

published on 03/24/2026 at 07:35, 2 months 25 days ago

Sanofi Releases Q1 2026 Aide-Mémoire to Support Financial Analysis

Innovation Biopharma Sanofi Financial Modeling Q1 2026 Results
BRIEF

published on 03/24/2026 at 07:35, 2 months 25 days ago

Sanofi's Q1 2026 financial guide is now online

Investors Quarterly Results Sanofi Financial Document Q1 2026
PRESS RELEASE

published on 03/24/2026 at 07:30, 2 months 25 days ago

Press release: Availability of the Q1 2026 aide-mémoire
Sanofi announces availability of Q1 2026 aide-mémoire for financial modelling purposes. Details on non-comparable items, currency impact, and share count included. Results to be published on April 23, 2026

Sanofi Results Aide-mémoire Financial Modelling Q1 2026
BRIEF

published on 03/18/2026 at 07:05, 3 months ago

Sanofi's Venglustat Earns Breakthrough Therapy Designation for Gaucher Disease Type 3

FDA Sanofi Breakthrough Therapy Venglustat Gaucher Disease
BRIEF

published on 03/18/2026 at 07:05, 3 months ago

Sanofi: Breakthrough Therapy Designation for venglustat in the United States

FDA Sanofi Venglustat Medical Discovery Gaucher's Disease
PRESS RELEASE

published on 03/18/2026 at 07:00, 3 months ago

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglustat receives Breakthrough Therapy designation in the US for type 3 Gaucher disease, a rare lysosomal storage disorder. Positive results from the LEAP2MONO study show significant improvements in neurological symptoms

Sanofi Breakthrough Therapy Venglustat Gaucher Disease Neurological Symptoms
BRIEF

published on 03/05/2026 at 09:21, 3 months 13 days ago

Sanofi Nominates Christel Heydemann as Independent Director

Corporate Governance Board Appointment Diversity Sanofi Christel Heydemann
BRIEF

published on 03/05/2026 at 09:21, 3 months 13 days ago

Sanofi: proposal to appoint Christel Heydemann as an independent director

Board Of Directors Appointment Diversity Sanofi Christel Heydemann
PRESS RELEASE

published on 03/05/2026 at 09:16, 3 months 13 days ago

Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi's Board of Directors proposes appointment of Christel Heydemann as independent director, renewing mandates, and thanking Patrick Kron. Heydemann brings expertise in industrial and digital transformation, strengthening governance diversity

Board Of Directors Governance Diversity Sanofi Christel Heydemann

Published on 06/19/2026 at 00:00, 25 minutes ago

Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/18/2026 at 23:55, 30 minutes ago

Relevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board Member
Published on 06/18/2026 at 23:30, 55 minutes ago

American Critical Minerals Extends Early Warrant Exercise Incentive Program
Published on 06/18/2026 at 23:00, 1 hour 25 minutes ago

Jaguar Mining Inc. Annual General Meeting of Shareholders Voting Results
Published on 06/18/2026 at 18:00, 6 hours 25 minutes ago

BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4

View all ACCESSWIRE

Published on 06/18/2026 at 22:35, 1 hour 50 minutes ago

Bitmine Immersion Technologies Announces Cash Dividend of $0.1056 per Share of 9.50% Series A Perpetual Preferred Stock
Published on 06/18/2026 at 22:00, 2 hours 25 minutes ago

Blue Cap AG: Closing of the Acquisition of Janoschka AG Successfully Completed
Published on 06/18/2026 at 18:55, 5 hours 30 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:55, 5 hours 30 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:30, 5 hours 55 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS

Published on 06/18/2026 at 18:00, 6 hours 25 minutes ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 6 hours 40 minutes ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 6 hours 46 minutes ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 13:00, 11 hours 25 minutes ago

Edenred statement
Published on 06/18/2026 at 09:06, 15 hours 19 minutes ago

Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany

View all LES ECHOS COMFI WIRE

News